Skip to content

Sysmex America receives FDA clearance for CN-6000™ hemostasis analyzer

Chicago, June 25, 2025 – Sysmex America, Inc., a leading provider of diagnostic solutions for hematology, hemostasis, urinalysis, flow cytometry, and informatics, has received U.S. Food and Drug Administration (FDA) clearance for the CN-6000™ automated hemostasis analyzer. The clearance includes reagents for five common hemostasis tests: Prothrombin Time (PT) and PT INR with Dade® Innovin®, Activated Partial Thromboplastin Time (APTT) with Dade® Actin® FSL, Fibrinogen (Fbg) with Dade® Thrombin Reagent, Antithrombin (AT) with INNOVANCE® Antithrombin, and D-Dimer with INNOVANCE® D-Dimer. “Our hemostasis solutions combine advanced technology, reliable reagents, and award-winning service to provide laboratories with accurate results for diagnosing bleeding or clotting disorders,” said Dan Zortman, CEO of Sysmex America. The CN-6000™ offers high throughput and fully automated testing in a space-saving design that can be adapted to the needs of various laboratories. An optional sample loader with expandable capacity is available for high-volume laboratories.… 

Acera Surgical Expands Restrata® Application with New FDA Clearance

  • News

ST. LOUIS, June 25, 2025 – Acera Surgical, a leader in the development of synthetic electrospun materials for soft tissue repair, has received additional 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Restrata® product. The new clearance expands the clinical application of the fully synthetic, absorbable electrospun matrix, which is now approved for soft tissue reinforcement in addition to wound healing. This applies to Restrata Sheet and Restrata Meshed. With the expanded indication, Restrata can be used to reinforce soft tissue where weaknesses exist, such as under primary skin closures in plastic and reconstructive surgery or in closures with a risk of wound dehiscence. “This clearance is a significant advancement for our clinical partners and the commercial development of Restrata,” said Mike Finegan, CEO of Acera Surgical. “We offer a versatile solution that addresses diverse surgical needs with a single technology.” Restrata is used in… 

Medeologix Revolutionizes Medical Technology: PET Shrink Tubing in Just Three Weeks

SAN JOSE, June 25, 2025 – Medeologix, a leading provider in the manufacturing of medical devices, has announced a significant advancement in the production of high-quality PET shrink tubing. Thanks to innovative technologies, the company has reduced the delivery time to just three weeks – a new benchmark in the industry. Technological Breakthrough for Faster Delivery TimesThe reduction in delivery time was made possible by Medeologix's proprietary technology, which optimizes the entire manufacturing process. Through advanced process development, real-time monitoring, and precise control systems, the company ensures maximum efficiency while maintaining premium quality. “It’s not just about speed, but about the consistency and repeatability that are essential for mass production,” emphasizes Anant Hegde, Technical Director at Medeologix. The shortened delivery time applies to both standard and custom specifications. This allows medical device manufacturers to respond more quickly to market demands without compromising the quality of critical components such as catheters. Customized… 

Breakthrough in Organoid Research: Liver Organoid Developed with Its Own Blood Vessels

  • News

Cincinnati, June 25, 2025 – Scientists at Cincinnati Children’s Hospital Medical Center and their partners in Japan have achieved a groundbreaking advance in organoid technology: they developed liver tissue that forms its own functional blood vessels. This milestone, published on June 25, 2025, in Nature Biomedical Engineering, could open new treatment possibilities for people with hemophilia and other bleeding disorders and advance the development of transplantable liver tissues. Research led by Takanori Takebe The project, led by Takanori Takebe, director of commercial innovation at the Center for Stem Cell and Organoid Research and Medicine (CuSTOM), is the result of nearly ten years of research. The study was supported by Takeda Pharmaceutical Company, the Institute of Science Tokyo, and the Ichan School of Medicine at Mount Sinai, among others. “Our research is a significant step toward mimicking the complex cellular interactions of liver development,” explains Takebe. “The ability to create functional sinusoidal vessels…” 

Canada Opens Application Period for AI Compute Access Fund: Funding for SMEs in Artificial Intelligence

Ottawa, June 25, 2025 – The Canadian government today opened the application period for the AI Compute Access Fund, a key element of the Canadian Sovereign AI Compute Strategy. With up to CAD 300 million, the fund will provide small and medium-sized enterprises (SMEs) with affordable access to high-performance computing capacity to advance innovative AI products and solutions developed in Canada. Fund Objectives: Innovation and Economic Growth The AI Compute Access Fund is part of a broader CAD 2 billion investment from Budget 2024, aimed at strengthening Canada’s AI ecosystem, increasing productivity, and promoting the adoption of AI across various sectors. SMEs in areas such as life sciences, energy, and advanced manufacturing, in particular, are expected to benefit from affordable access to high-performance computing resources. “The AI Compute Access Fund will remove barriers and enable companies and entrepreneurs to create solutions developed in Canada,” stated…

Government of Canada opens applications for the AI Compute Access Fund

As artificial intelligence (AI) continues to shape our world, the Government of Canada seeks to harness AI’s opportunities, mitigate its risks and foster trust. With strategic government investments and support for responsible AI adoption, Canada will grow its AI ecosystem and enhance productivity across the country. Today, the Government of Canada opened applications for the AI Compute Access Fund, a key initiative under the Canadian Sovereign AI Compute Strategy. This fund will provide up to $300 million for affordable access to compute power for small and medium-sized enterprises (SME) to develop made-in-Canada AI products and solutions. A due diligence assessment of each project proposal will be conducted to evaluate: Investing in AI is vital to building the strongest economy in the G7. The Government of Canada remains steadfast in supporting the nation’s AI ecosystem with strategic investments that will drive both economic growth and responsible technological advancement. With this commitment, the government…

The great challenge of challenges: Settling accounts with a word that means everything and nothing

Once upon a time, there was a word that made a steep career in the halls of politics and the editorial offices of the media: challenge. A term so flexible, so harmless, so non-committal that it could be sprinkled like an all-purpose cleaner over any dirty reality to cast it in a shiny, optimistic light. Where "problems" once lurked – those unpleasant, prickly things that cried out for solutions – "challenges" now grew like bureaucratic flowers in a compromise field. This satire takes on the word and its inflationary use in politics and the media, breaks it down into its individual parts, and asks: Why have we stopped calling problems problems, and what does that say about our time? The rise of the word: From sports metaphor to political universal weapon Let's imagine a press conference, somewhere in a capital city characterized by glass facades and overpriced rents…

The inevitable collapse of Nina Warken's health reform

  • News

The health reform led by Federal Minister of Health Nina Warken (CDU), who has been in office since May 2025, faces significant problems that could seal its failure. One of the central issues is the high number of doctor's offices that will close due to age in the coming years. This phenomenon, often referred to as "physician shortage," exacerbates existing supply bottlenecks in the German healthcare system and presents a tremendous challenge to reform efforts. The following provides a detailed analysis of the situation, focusing on age-related practice closures, examining the potential impact on reform goals, and highlighting the structural and political hurdles that make the reform's failure likely. 1. Background of the Health Reform under Nina Warken Nina Warken took office as Federal Minister of Health in May 2025 and faces the task of reforming a healthcare system suffering from chronic underfunding, inefficient structures, and a growing shortage of skilled workers... 

Why Elon Musk could buy the US media company LabNews Media LLC

Elon Musk, one of the most influential entrepreneurs and innovators of our time, is known for his ambitious projects ranging from electric mobility and space travel to artificial intelligence. His recent activities suggest that he is increasingly showing interest in the media landscape. A potential acquisition of the US media company LabNews Media LLC, which operates the portals labnews.ai/, pugnalom.io, and augenauf.blog, could be plausible. This article analyzes the possible reasons for such an acquisition, ranging from strategic considerations and ideological motives to technological synergies. It examines the potential benefits for Musk, the impact on the media landscape, and the specific characteristics of the mentioned platforms. 1. Strategic Expansion of Influence in the Media World Elon Musk has repeatedly emphasized his desire to change the way information is disseminated and consumed. His acquisition of Twitter (now X) in 2022 was a... 

New designer drugs pose a growing threat to traffic safety in the U.S.

  • News

A new study in Frontiers in Toxicology highlights the urgent need to expand routine post-traffic accident testing to include novel drugs. It is the first comprehensive investigation to examine the contribution of a wide range of so-called “novel psychoactive substances” to U.S. traffic accidents. “Here we show that novel psychoactive substances (NPS), a class of drugs whose prevalence has rapidly increased over the last 15 years, play a role in traffic accidents,” said Dr. Roy Gerona, one of the study’s corresponding authors and an associate professor at the University of California, San Francisco. NPS, colloquially known as “designer drugs,” “legal highs,” “herbal incense,” and “bath salts,” are drugs that are not covered by the United Nations Single Convention on Narcotic Drugs of 1961 or the Convention on Psychotropic Substances of 1971, but are classified by experts as harmful to health. Examples include designer benzodiazepines, synthetic cathinones and cannabinoids, piperazines, and